IP Library Patent Application 11826385
Patent Application
App. No. 11/826,385

Genetic inhibition by double-stranded RNA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/826,385
Abstract

A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The present invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.

Claims (26)

1 - 21 . (canceled)

22 . A method to inhibit expression of a target gene comprising:

(a) providing an organism containing a target cell, wherein the target cell contains the target gene and the target gene is expressed in the target cell;

(b) contacting a ribonucleic acid (RNA) with the organism, wherein the RNA is comprised of a double-stranded structure with duplexed ribonucleic acid strands and one of the strands is able to duplex with a portion of the target gene; and

(c) introducing the RNA into the target cell, thereby inhibiting expression of the target gene.

23 . The method of claim 22 in which the organism is an animal.

24 . The method of claim 22 in which the organism is a plant.

25 . The method of claim 22 in which the organism is an invertebrate animal.

26 . The method of claim 22 in which the organism is a nematode.

27 . The method of claim 26 in which a formulation comprised of the RNA is applied on or adjacent to a plant, and disease associated with nematode infection of the plant is thereby reduced.

28 . The method of claim 22 in which the identical nucleotide sequence is at least 50 nucleotides in length.

29 . The method of claim 22 in which the expression of the target gene is inhibited by at least 10%.

30 . The method of claim 22 in which the RNA is introduced within a body cavity of the organism and outside the target cell.

31 . The method of claim 22 in which the RNA is introduced by extracellular injection into the organism.

32 . The method of claim 22 in which the organism is contacted with the RNA by feeding the organism food containing the RNA.

33 . The method of claim 32 in which a genetically-engineered host transcribing the RNA comprises the food.

34 . The method of claim 22 in which at least one strand of the RNA is produced by transcription of an expression construct.

35 . The method of claim 35 in which the organism is a nematode and the expression construct is contained in a plant, and disease associated with nematode infection of the plant is thereby reduced.

36 . A cell containing an expression construct,

wherein the expression construct transcribes at least one ribonucleic acid (RNA) and the RNA forms a double-stranded structure with duplexed strands of ribonucleic acid,

whereby said cell contains the double-stranded RNA structure and is able to inhibit expression of a target gene when the RNA is contacted with an organism containing the target gene.

37 . A transgenic animal containing said cell of claim 36 .

38 . A transgenic plant containing said cell of claim 36 .

39 . A kit comprising reagents for inhibiting expression of a target gene in a cell,

wherein said kit comprises a means for introduction of a ribonucleic acid (RNA) into the cell in an amount sufficient to inhibit expression of the target gene, and

wherein the RNA has a double-stranded structure with an identical nucleotide sequence as compared to a portion of the target gene.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2014
From: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
To: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
Reel/Frame 032685/0158 →
SECURITY AGREEMENT Recorded Feb 15, 2012
From: MARINA BIOTECH, INC; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
Reel/Frame 027712/0200 →
RELEASE OF SECURITY INTEREST Recorded Jul 30, 2010
From: CEQUENT PHARMACEUTICALS, INC.
To: MARINA BIOTECH, INC. (F/K/A MDRNA, INC.)
Reel/Frame 024767/0466 →